These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

374 related items for PubMed ID: 30027855

  • 1. Amplified Crosstalk Between Estrogen Binding and GFR Signaling Mediated Pathways of ER Activation Drives Responses in Tumors Treated with Endocrine Disruptors.
    Suba Z.
    Recent Pat Anticancer Drug Discov; 2018; 13(4):428-444. PubMed ID: 30027855
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium.
    Labrie F, Labrie C, Bélanger A, Simard J, Gauthier S, Luu-The V, Mérand Y, Giguere V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R.
    J Steroid Biochem Mol Biol; 1999; 69(1-6):51-84. PubMed ID: 10418981
    [Abstract] [Full Text] [Related]

  • 4. The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance.
    Suba Z.
    Drug Des Devel Ther; 2015; 9():4341-53. PubMed ID: 26273195
    [Abstract] [Full Text] [Related]

  • 5. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens.
    Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS.
    Mol Endocrinol; 1996 Mar; 10(3):230-42. PubMed ID: 8833652
    [Abstract] [Full Text] [Related]

  • 6. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
    Osborne CK, Shou J, Massarweh S, Schiff R.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 2):865s-70s. PubMed ID: 15701879
    [Abstract] [Full Text] [Related]

  • 7. Rosetta Stone for Cancer Cure: Comparison of the Anticancer Capacity of Endogenous Estrogens, Synthetic Estrogens and Antiestrogens.
    Suba Z.
    Oncol Rev; 2023 Jan 15; 17():10708. PubMed ID: 37152665
    [Abstract] [Full Text] [Related]

  • 8. Targeting the crosstalk between estrogen receptors and membrane growth factor receptors in breast cancer treatment: Advances and opportunities.
    Yan S, Ji J, Zhang Z, Imam M, Chen H, Zhang D, Wang J.
    Biomed Pharmacother; 2024 Jun 15; 175():116615. PubMed ID: 38663101
    [Abstract] [Full Text] [Related]

  • 9. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
    Saha T, Makar S, Swetha R, Gutti G, Singh SK.
    Eur J Med Chem; 2019 Sep 01; 177():116-143. PubMed ID: 31129450
    [Abstract] [Full Text] [Related]

  • 10. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ, Jordan VC.
    Cancer Res; 1996 May 15; 56(10):2321-30. PubMed ID: 8625307
    [Abstract] [Full Text] [Related]

  • 11. William L. McGuire Memorial Symposium. Estrogen receptors: ligand discrimination and antiestrogen action.
    Katzenellenbogen BS, Fang H, Ince BA, Pakdel F, Reese JC, Wooge CH, Wrenn CK.
    Breast Cancer Res Treat; 1993 May 15; 27(1-2):17-26. PubMed ID: 8260727
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Studies on mechanisms of estrogen and antiestrogen action in human breast cancer.
    Horwitz KB, McGuire WL.
    Recent Results Cancer Res; 1980 May 15; 71():45-58. PubMed ID: 6988916
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
    Massarweh S, Schiff R.
    Endocr Relat Cancer; 2006 Dec 15; 13 Suppl 1():S15-24. PubMed ID: 17259554
    [Abstract] [Full Text] [Related]

  • 20. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K, Thu N, Saville B, Safe S.
    Mol Endocrinol; 2003 May 15; 17(5):804-17. PubMed ID: 12576490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.